Contineum Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Contineum Therapeutics, Inc. (CTNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-07-30
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $1.10M.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $700.00K, a 250.00% increase year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $100.00K, a 50.00% decline year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $300.00K, a 85.71% decline from fiscal 2024.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $2.10M, a 250.00% increase from fiscal 2023.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $600.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.80M 10-Q · filed 2026-07-30 | $1.80M derived: sum of 3 quarters · filed 2026-07-30 | $1.90M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-05 | $700.00K derived: sum of 2 quarters · filed 2026-05-05 | $800.00K derived: sum of 3 quarters · filed 2026-05-05 | $800.00K derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $100.00K derived: sum of 2 quarters · filed 2026-03-05 | $100.00K derived: sum of 3 quarters · filed 2026-07-30 | $300.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $100.00K derived: sum of 2 quarters · filed 2026-07-30 | $300.00K 10-Q · filed 2025-10-30 | $1.80M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $200.00K 10-Q · filed 2026-07-30 | $1.70M derived: sum of 3 quarters · filed 2026-07-30 | $1.90M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-05 | $1.70M derived: sum of 2 quarters · filed 2026-05-05 | $1.90M derived: sum of 3 quarters · filed 2026-05-05 | $2.00M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.70M derived: sum of 2 quarters · filed 2026-03-05 | $1.80M derived: sum of 3 quarters · filed 2026-03-05 | $2.10M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $200.00K 10-Q · filed 2024-11-06 | $300.00K derived: sum of 2 quarters · filed 2025-08-05 | $600.00K 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $400.00K 10-Q · filed 2025-08-05 | $100.00K 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | $600.00K 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $400.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |